Ted Michelakos, MD

Surgeon-scientist, @UChicagoSurgery fellow, @MGHSurgery resident, @UOAofficial alum. Bagel enthusiast 🇬🇷

[Motaz Qadan, MD, PhD @motazqadan]

For IMG dreamers out there looking to be inspired, the 3 leaders of the historic xenotransplanted kidney press release below are all IMGs. Never give up on your dreams no matter how far they may seem. Impossible is nothing

[Ted Michelakos, MD @TMichelakos]

@SusanaFortichS @adriancoleoglou @CamilaFrancoMe @jfranfigueroa @JoseODEL90 @chris_kalti @UPMC @DrMigueQC @CedarsSinai #IMG from 🇬🇷 here! Props to all IMGs for their resilience and hard work. Good luck to all those participating in #Match2023

[Ted Michelakos, MD @TMichelakos]

@DrDimitrios How about doing this every single day?

[Ted Michelakos, MD @TMichelakos]

Surgery is addictive

[Ted Michelakos, MD @TMichelakos]

@IEMcElroy At least child care is provided to all residents for free. JK

[Ted Michelakos, MD @TMichelakos]

@RodGerardo Actually see the patient before calling, and never say “my senior told me x”

[Ted Michelakos, MD @TMichelakos]

66% are right: totally different, as explained by @ZhiVenFongMD and in link. Yet they are used interchangeably very frequently. Need for more rigorous statistical review by journals?
https://t.co/nxwKIYSzcJ

[Ted Michelakos, MD @TMichelakos]

“Multivariate” or “multivariable”?

[Ted Michelakos, MD @TMichelakos]

@ZhiVenFongMD @HalletJulie @cchildersmd @LVSelbs Agree. Most use multivariate but mean multivariable. Ref: https://t.co/nxwKIYSzcJ

[Ted Michelakos, MD @TMichelakos]

Overcoming radioresistance in mesenchymal tumors: targeting cancer stem cells with disulfiram/Cu might be key. Check out our latest study: https://t.co/aVkfKdn1wt

[Ted Michelakos, MD @TMichelakos]

Dynamic prognostication metrics are underutilized esp. for diseases w/ steep survival curves like #PancreaticCancer. Check out our latest @JournalofGISurg paper on conditional survival in TNT-treated PDAC. @MGHSurgery https://t.co/XfuLOjTZiS

[Ted Michelakos, MD @TMichelakos]

@bnwomeh @TomVargheseJr @JonathanGroner @StefanouAmalia @cardiojaydoc02 @jmills1955 @DissanaikeMD @Dr_AMeagher @ekhaese_obos @InduPartha

[Ted Michelakos, MD @TMichelakos]

@SyedAAhmad5 Agree. Interestingly, in R1 cohort, those who got IORT did better (37 vs 21mo), and in non-IORT cohort R1 did much worse.

[Ted Michelakos, MD @TMichelakos]

Does #IORT mitigate the effect of an R1 resection in TNT-treated #PDAC? Find out in our latest @AnnSurgOncol paper https://t.co/gJ8AJpLJSh (spoiler: it does)

[Ted Michelakos, MD @TMichelakos]

@Pete_Labib @guyshrubsole Interesting, will check it out

[Ted Michelakos, MD @TMichelakos]

Reading list Nov-Dec 2020. Open to recommendations. What are you reading? #SurgeonsWhoRead

[Ted Michelakos, MD @TMichelakos]

@ZhiVenFongMD @TheNotoriousHPB @motazqadan @SyedAAhmad5 @DrJashDatta @Gio_Marchegiani @gimalleo @FlavioRochaMD @DrRABurkhart @surgeonweiss Very promising work. Important that this #exosome analysis method is not only ultra-sensitive, but also rapid & low-cost -> ⬆️clinical applicability

[I E McElroy MD, MPH: @iemcelroymd.bsky.social @IEMcElroy]

What do you do when you get turned into a meme?

You use it as your call to action to address systemic racism and perpetuation of White Supremacy in medicine and surgery.

It’s time to get comfortable with being uncomfortable.

https://t.co/eR5PaplHR7

[maggie rose connolly, MD @returnofthemags]

Looking forward to chatting with the @MGHSurgery residents about our research and professional development experience at the next MGH Applicant Q&A on Tuesday 10/27 at 7P EST.

Sign up here: https://t.co/fH1HOd2tr9

#ILookLikeASurgeon #Match2021 #GenSurgMatch2021

[Ted Michelakos, MD @TMichelakos]

@SyedAAhmad5 @GregWilson152 Can’t beat the Aquanaut either!! 👏🏼